European Heart Journal — Cardiovascular Pharmacotherapy最新文献_第9页

ESC Guidelines revisited. 修订ESC指南。

IF 7.1

European Heart Journal — Cardiovascular Pharmacotherapy Pub Date : 2020-04-01 DOI: 10.1093/ehjcvp/pvz083

Heinz Drexel, Stephan Milbradt

引用次数: 0

Lipids and antithrombotic treatment. 血脂和抗血栓治疗。

IF 7.1

European Heart Journal — Cardiovascular Pharmacotherapy Pub Date : 2020-04-01 DOI: 10.1093/ehjcvp/pvaa014

Stefan Agewall

引用次数: 0

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. 达比加群、利伐沙班和阿哌沙班治疗房颤的有效性和安全性的比较:一项全国性队列研究。

IF 7.1

European Heart Journal — Cardiovascular Pharmacotherapy Pub Date : 2020-04-01 DOI: 10.1093/ehjcvp/pvz086

Ole-Christian W Rutherford, Christian Jonasson, Waleed Ghanima, Fabian Söderdahl, Sigrun Halvorsen

{"title":"Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.","authors":"Ole-Christian W Rutherford, Christian Jonasson, Waleed Ghanima, Fabian Söderdahl, Sigrun Halvorsen","doi":"10.1093/ehjcvp/pvz086","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvz086","url":null,"abstract":"Aims: The aim of this study was to compare the risk of stroke or systemic embolism (SE) and major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and apixaban in routine clinical practice.Methods and results: Using nationwide registries in Norway from January 2013 to December 2017, we established a cohort of 52 476 new users of non-vitamin K antagonist oral anticoagulants (NOACs) with AF. Users of individual NOACs were matched 1:1 on the propensity score to create three pairwise-matched cohorts: dabigatran vs. rivaroxaban (20 504 patients), dabigatran vs. apixaban (20 826 patients), and rivaroxaban vs. apixaban (27 398 patients). Hazard ratios (HRs) for the risk of stroke or SE and major bleeding were estimated. In the propensity-matched comparisons of the risk of stroke or SE, the HRs were 0.88 [95% confidence interval (CI) 0.76-1.02] for dabigatran vs. rivaroxaban, 0.88 (95% CI 0.75-1.02) for dabigatran vs. apixaban, and 1.00 (95% CI 0.89-1.14) for apixaban vs. rivaroxaban. For the risk of major bleeding, the HRs were 0.75 (95% CI 0.64-0.88) for dabigatran vs. rivaroxaban, 1.03 (95% CI 0.85-1.24) for dabigatran vs. apixaban, and 0.79 (95% CI 0.68-0.91) for apixaban vs. rivaroxaban.Conclusion: In this nationwide study of patients with AF in Norway, we found no statistically significant differences in risk of stroke or SE in propensity-matched comparisons between dabigatran, rivaroxaban, and apixaban. However, dabigatran and apixaban were both associated with significantly lower risk of major bleeding compared with rivaroxaban.","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"75-85"},"PeriodicalIF":7.1,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvz086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37546479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 58

An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. ESC心血管药物治疗工作组关于他汀类药物依从性和新型降脂药物实施的专家意见论文:需要克服的障碍。

IF 7.1

European Heart Journal — Cardiovascular Pharmacotherapy Pub Date : 2020-04-01 DOI: 10.1093/ehjcvp/pvz079

Heinz Drexel, Andrew J S Coats, Ilaria Spoletini, Claudio Bilato, Vincenzo Mollace, Pasquale Perrone Filardi, Giuseppe M C Rosano

引用次数: 37